Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis.
We present two patients with rheumatoid arthritis (RA) who developed necrotizing crescentic glomerulonephritis (NCGN) during etanercept therapy. Both patients developed proteinuria and hematuria, and one progressed to renal failure. Renal biopsy revealed NCGN. In both patients, nephritis improved following discontinuation of etanercept and administration of prednisolone. Physicians should be aware of etanercept-induced GN in patients with RA on anti-tumor necrosis factor therapy.
Kaneko
Kayoko
K
Department of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Nanki
Toshihiro
T
Hosoya
Tadashi
T
Mizoguchi
Fumitaka
F
Miyasaka
Nobuyuki
N
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D005260:Female; D005921:Glomerulonephritis / Q000139:chemically induced* / Q000473:pathology; D006417:Hematuria / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008875:Middle Aged; D009336:Necrosis; D011507:Proteinuria / Q000139:chemically induced / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor; D051437:Renal Insufficiency / Q000139:chemically induced / Q000473:pathology / Q000652:urine; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept